• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 24th April 2012

New Research on VBP: Disease Severity and Unmet Need in the UK

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Koonal Shah

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe or are associated with the greatest unmet need.

Koonal Shah

Koonal Shah

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe or are associated with the greatest unmet need.  This suggests combining severity of disease and unmet need into a single metric.  A literature review reveals that this approach has not been studied adequately (or perhaps at all) to date, either in the UK or elsewhere.

The Department of Health’s Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) was asked by the Department to conduct an empirical study of society’s resource allocation preferences to obtain weights for burden of illness, therapeutic improvement and end-of-life.  The objective would be to apply these, under the coming VBP system, to assessments of both new technologies and displaced activities.

The EEPRU study defines burden of illness as distance from “normal” health; the measure combines health status with the effects of existing standard therapy on both length and quality of life.  The value of existing therapy, then, is in its contribution to the degree of burden.  Not considered explicitly in the EEPRU study are issues raised by the definition of unmet need implied in the VBP Consultation Document – i.e. that “unmet need” means that no treatment is available at all.

Data collection for the EEPRU study is being conducted online, using discrete choice experiments to elicit preferences.  Stakeholders have expressed concern about the limited scope of the EEPRU study in that it does not examine whether people have preferences about the availability of alternative treatments.

To address some of these issues, OHE currently is performing a small study, funded by an unrestricted research grant from the ABPI.  Based on interviews with members of the general public, it is intended to develop a more nuanced understanding of the extent of societal support for basing health care resource priorities on disease severity and unmet need.

The OHE survey will be administered in face-to-face interviews conducted by trained interviewers with experience in conducting health care preference studies.  Questions will be designed to identify respondents’ levels of support for policies that give greater weight to treatments that address disease severity and unmet medical need than to those that do not.  The research also will address whether, controlling for disease severity, unmet need per se affects societal preferences regarding priorities for treatment.  In this study, respondents also will be asked probing follow-up questions intended to elicit qualitative information about the thinking behind their choices.

This study will provide important, preliminary information about how disease severity and unmet need should be measured and how best to capture societal preferences.  The main points we expect the research to address include the following:

  1. Whether members of the public would support a policy that uses combined disease severity and unmet need as a criterion for priority setting
  2. What societal preferences about disease severity and unmet need can be observed
  3. Whether preferences regarding unmet need depend at least in part on disease severity
  4. The likely reasons for the preferences observed
  5. The strength of the preferences observed

The OHE study, then, will both complement the EEPRU study by exploring additional possible attributes and provide additional evidence about whether preferences regarding unmet need depend on disease severity.  It can help define what further research is essential to produce valid measures.

The OHE research team for the project is Koonal Shah and Nancy Devlin.  Results are anticipated in summer 2012 and will be published as an OHE Research Paper.

  • Value-Based Pricing
  • Value, Affordability, and…
  • Grants

Related News

  • News
  • December 2019

New OHE Research Funding: Improving Labour Productivity in Primary Care

Read more
  • News
  • October 2019

Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase

Read more
  • News
  • May 2019

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Read more
  • News
  • September 2018

UKRI Funds OHE Collaboration in Student Mental Health Research Network

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!